Biotech · Public company · Waltham, MA, US

Upstream Bio, Inc.

Ticker UPB · SEC CIK 0002022626

Track this companyFree. Adds Upstream Bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials42 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

VerekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VerekitugPhase 2 · Severe AsthmaClinicalTrials.gov · fetched Nov 12, 2026
Verekitug (UPB-101)Phase 2 · Chronic Rhinosinusitis With Nasal PolypsClinicalTrials.gov · fetched Nov 12, 2026
Verekitug (UPB-101)Phase 2 · Severe AsthmaClinicalTrials.gov · fetched Nov 12, 2026

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 2, 2025ClinicalTrials.gov NCT06981078 · fetched Nov 12, 2026
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)PHASE2 · ACTIVE_NOT_RECRUITING · started May 21, 2025ClinicalTrials.gov NCT06966479 · fetched Nov 12, 2026
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)PHASE2 · COMPLETED · started Feb 27, 2024ClinicalTrials.gov NCT06196879 · fetched Nov 12, 2026
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsPHASE2 · COMPLETED · started Dec 18, 2023ClinicalTrials.gov NCT06164704 · fetched Nov 12, 2026